<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Catastrophic <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (CAPS) is a life-threatening condition characterized by small-vessel <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> and a rapid <z:hpo ids='HP_0003674'>onset</z:hpo> of multiorgan system failure associated with systemic <z:mp ids='MP_0001845'>inflammatory response</z:mp> syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>Current treatment options include <z:chebi fb="2" ids="50249">anticoagulants</z:chebi>, <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, plasma exchange, and intravenous immunoglobulin, but these are not always effective </plain></SENT>
<SENT sid="2" pm="."><plain>Rituximab, a chimeric anti-CD20 monoclonal antibody, may help eliminate autoreactive B cells and thus limit the rapid inflammatory process involved in CAPS </plain></SENT>
<SENT sid="3" pm="."><plain>We describe the use of rituximab in the successful initial management of a probable case of pediatric CAPS </plain></SENT>
</text></document>